Interleukin 17F level and interferon β response in patients with multiple sclerosis.

ABSTRACT:

Importance

High serum levels of interleukin 17F (IL-17F) at baseline have been associated with suboptimal response to interferon beta in patients with relapsing-remitting multiple sclerosis.

Objective

To further investigate the role of IL-17F in predicting treatment response to interferon beta-1b in patients with relapsing-remitting multiple sclerosis using the Singulex Erenna IL-17F immunoassay.

Design, setting, and patients

Serum samples were analyzed from 239 randomly selected patients treated with interferon beta-1b, 250 μg, for at least 2 years in the Betaferon Efficacy Yielding Outcomes of a New Dose Study.

Exposure

Treatment with interferon beta-1b, 250 μg, for at least 2 years.

Main outcome measures

Levels of IL-17F at baseline and month 6 as wel

SUBMITTER: Hartung HP 

PROVIDER: S-EPMC4290836 | biostudies-literature | 2013 Aug

REPOSITORIES: biostudies-literature